DIA Housing Now Open!
DIA encourages you to select an official DIA hotel for your stay.
Track 9: Translational Science: Preclinical/Clinical and Product Development
With 22 sessions specific to Preclinical/Clinical and Product Development, DIA’s Translational Science track covers the intersections of preclinical research, clinical research, and product development. Sessions explore current and innovative methods to:
- Evaluate scientific and medical information
- Optimize clinical trial enrollment and novel technique for trial retention
- Identify new clinical questions and gaps in care
- Expedite drug development using novel protocol techniques
Highlights in Preclinical/Clinical and Product Development
- Wearables
- Patient-reported outcomes in drug development
- Innovative trial designs to accelerate decision-making
- Updates to ICH E17
DIA recommends this track and associated sessions to professionals involved in: clinical operations, clinical research, safety and pharmacovigilance, project management, patient centricity, and statistics.
Sessions in Preclinical/Clinical and Product Development
Sunday, June 18 | Short Courses
Monday, June 19
- Calling All Angels to the Valley of Death
- Exploration of PK/PD in NDA Enabling or Early Proof of Concept Studies
- Hybrid Studies
- GBM AGILE: A Transformative Global Adaptive Platform Clinical Trial
Drug Repurposing: Where Will it Take Us? The Future of Patient Engagement: Measuring What Matters The Evolution of Evidence Generation: Real World Evidence and the Next Generation of Decision-Making
Tuesday, June 20
- At the Cornerstone of Wearable Technology and Patient-Focused Clinical Trial Endpoints
- Patient-Reported Outcomes (PROs): Hot Topics - Part 1 and Part 2
- Use of Novel Trial Designs to Accelerate Decision Making: To 'P' No More
- Master Protocols: New Approaches to Enrolling Hard-to-Find Subjects and Expediting Drug Development
- Novel Techniques for Improving Clinical Trial Subject Retention
- What Question Are You Trying to Answer? The Use of Estimands, Potential Revisions to ICH E-9, and the Impact to Trial Design and Analysis
- Audits and Agency Inspections of Risk-Based Monitored Studies: The Results Are In…
- Creating Adaptive Contents for a Multichannel World
- Effective Team Management in Global Trials
- Combination Products
Paying for Value in Biopharmaceuticals: Trends in the United States People Will Talk: Gathering Insights from Digital Listening
Wednesday, June 21
- Optimizing Early Clinical Strategies to Support Breakthrough Therapy Designation
- What Do the Experts Believe? Translating Expert Knowledge and Judgment Into a Quantitative Belief Distribution
- Patient-Relevant, Fit-For-Purpose Endpoints: If You Can Believe It, You Can Achieve It
- Multiregional Clinical Trials and the ICH E17
- Experimental Studies: New Approaches to Study Designs to Facilitate Early Phase Decision-Making
- Safety Issues in First-in-Human Studies
- FDA, NIH, and TransCelerate Collaborate to Accelerate Drug Development Through Protocol Harmonization
- Patient Perspective
- Medical Affairs and KOL Management
Does Diversity Matter in Clinical Trials?
Progress in Pediatric Therapeutics
Thursday, June 22
- Trial Master File: MHRA/EMA Inspections and Sponsor Audit Learnings
- Of Course My Data Has Integrity…And I Can Prove It
- Evolving Clinical Trial Guidance and Regulations: Am I Ready?
EMA/FDA Question Time
Translational Medicine and Regulatory Science: How We Think at DIA
Read the latest insights on Translational Medicine and Regulatory Science from DIA's digital magazine, the Global Forum, and DIA’s print journal, Therapeutic Innovation and Regulatory Science (TIRS).
Need More on Translational Medicine and Regulatory Science?
DIA’s Learning portfolio offers multiple face-to-face and online training opportunities. Our courses provide comprehensive coverage of the full discovery, development, and life cycle management of health care products. DIA’s unique multidisciplinary environment provides learning opportunities not only in participants’ respective fields, but also in related fields—lending new perspectives that help teams collaborate more efficiently and effectively. DIA wants to ensure you’re prepared with the knowledge, solutions, and strategies you need to be successful in in today's complex global regulatory environment.
Click to learn about the Drug Development and Life Cycle Management and Clinical Trial Fundamentals eLearning Programs designed for professionals new to the field. DIA offers group rates to companies interested in purchasing eLearning modules for multiple users within a team.
Upcoming Online and Face-to-Face Learning
- New Drug Product Development and Life Cycle Management
- Global Regulatory Strategy and Drug Development in Asia-Pacific, Latin America, and Other Emerging Markets
- Innovative Statistical Approaches for Clinical Trials
- Adaptive Design